Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH – Get Free Report) insider Edwin Reisz sold 50,000 shares of the business’s stock in a transaction that occurred on Thursday, August 20th. The stock was sold at an average price of $11.50, for a total value of $575,000.00. Following the transaction, the insider owned 1,397,897 shares in the company, valued at approximately $16,075,815.50. This represents a 3.45% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Aveanna Healthcare Price Performance
NASDAQ:AVAH opened at $13.59 on Wednesday. Aveanna Healthcare Holdings Inc. has a one year low of $5.93 and a one year high of $13.98. The company has a debt-to-equity ratio of 4.47, a quick ratio of 1.16 and a current ratio of 1.16. The stock has a market cap of $2.97 billion, a PE ratio of 11.05, a P/E/G ratio of 0.96 and a beta of 1.90. The stock has a 50 day moving average price of $9.83 and a 200 day moving average price of $7.99.
Aveanna Healthcare (NASDAQ:AVAH – Get Free Report) last announced its quarterly earnings data on Thursday, August 13th. The company reported $0.22 EPS for the quarter, topping analysts’ consensus estimates of $0.17 by $0.05. The firm had revenue of $670.48 million for the quarter, compared to the consensus estimate of $638.61 million. Aveanna Healthcare had a return on equity of 80.70% and a net margin of 10.56%. Equities research analysts expect that Aveanna Healthcare Holdings Inc. will post 0.68 EPS for the current fiscal year.
Institutional Trading of Aveanna Healthcare
Wall Street Analysts Forecast Growth
AVAH has been the topic of several recent research reports. Royal Bank Of Canada boosted their price target on shares of Aveanna Healthcare from $10.00 to $16.00 and gave the company an “outperform” rating in a research report on Monday. Wall Street Zen cut shares of Aveanna Healthcare from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 15th. Stephens raised shares of Aveanna Healthcare from an “equal weight” rating to an “overweight” rating and lifted their target price for the stock from $10.00 to $11.00 in a research note on Friday, May 15th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Aveanna Healthcare in a report on Thursday, July 2nd. Finally, Truist Financial increased their price target on shares of Aveanna Healthcare from $11.00 to $15.00 and gave the company a “hold” rating in a research note on Monday. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $12.89.
Check Out Our Latest Stock Analysis on AVAH
Key Aveanna Healthcare News
Here are the key news stories impacting Aveanna Healthcare this week:
- Positive Sentiment: Royal Bank of Canada raised its price target to $16 from $10 and upgraded AVAH to “outperform.” The upgrade reinforces the bullish outlook following the stock’s recent rally. Benzinga analyst coverage
- Positive Sentiment: Truist Financial increased its price target to $15 from $11, although it maintained a “hold” rating. Other analysts have also raised targets after Aveanna exceeded quarterly earnings and revenue expectations. Benzinga analyst coverage
- Positive Sentiment: Aveanna reported quarterly EPS of $0.22 versus the $0.17 consensus estimate and revenue of $670.48 million versus expectations of $638.61 million. The earnings beat supports the improved analyst outlook and investor interest in the shares.
- Neutral Sentiment: Management will participate in the Jefferies Healthcare Services and Technology Conference on September 15. The presentation and one-on-one investor meetings could provide additional business updates, but the event is not an immediate financial catalyst. Aveanna conference announcement
- Negative Sentiment: Major shareholders, including Bain Capital- and J.H. Whitney-affiliated holders, disclosed substantial sales in a roughly $176 million offering. Additional sales by CEO Jeff Shaner, director Rodney Windley, and insider Edwin Reisz at $11.50 per share could weigh on sentiment and increase concerns about selling pressure, even though these holders retained sizable positions. Home Health Care News offering report
Aveanna Healthcare Company Profile
Aveanna Healthcare, Inc (NASDAQ: AVAH) is a national provider of in-home health care services, specializing in pediatric skilled nursing, therapy, and related support for medically complex and chronically ill children. The company delivers a range of clinical and therapeutic solutions designed to enable patients to receive care in the comfort of their own homes, reducing the need for hospital stays and long-term institutional care. Aveanna’s offerings include registered nursing, physical, occupational and speech therapy, behavioral health counseling, and durable medical equipment coordination.
In addition to pediatric home health services, Aveanna operates adult home health and personal care support programs, assisting elderly and disabled adults with daily living activities, medication management, and rehabilitation therapies.
Featured Stories
- Five stocks we like better than Aveanna Healthcare
- Pathward’s Credit Scare Tests Its Comeback Story
- Wiring the AI Boom: Rumble’s $13.7B Pivot
- StoneX: Too Far Too Fast?
- DICK’s Sporting Goods Faces Pain Now for a Bigger Prize
Receive News & Ratings for Aveanna Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aveanna Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.
